Success with In Vivo Examination of Cancerous Tissue via the Lumicell Imaging System During the Pivotal Trial will Propel the Technology Toward FDA Submission Newton, Mass., November 5, 2019 – Lumicell, Inc., an innovation leader in image guided cancer surgery, today announced it has begun its pivotal trial of the Lumicell Imaging System for breast cancer — a major milestone on its path toward FDA submission for approval. The two-arm, randomized pivotal study follows comp...

Pivotal trial expected to begin by end of 2019 for the Lumicell Imaging System for intraoperative detection and removal of residual cancer in breast-conserving surgery. Newton, Mass., August 19, 2019 — Lumicell, Inc. an innovation leader in image guided cancer surgery, today announced that it has completed enrollment in its Phase C feasibility clinical trial of the Lumicell Imaging System for breast cancer. With results from the Phase C feasibility trial expected in late 2019, Lumicell expects...

Positive Clinical Results in Breast Cancer Trial Shows Promise for Ovarian and Other Cancers Newton, Mass., April 10, 2019 — Lumicell, Inc. today announced that a feasibility study is underway at Massachusetts General Hospital in Boston to determine the initial safety and efficacy of its Lumicell System for in vivo imaging of metastases to the peritoneum from primary ovarian cancer, appendiceal cancer, gastrointestinal cancer and mesothelioma. The feasibility study is being...

Complete and Immediate Detection of Residual Cancer in Tumor Cavity During Lumpectomy Surgery Data Presented by Investigators from Massachusetts General Hospital’s Breast Program at 2017 San Antonio Breast Cancer Symposium Integrated LUM System Correctly Identified Residual Cancer Cells Across Breast Cancer Subtypes Wellesley, Mass., Dec. 7, 2017— Lumicell, Inc. today announced the presentation of clinical data from its ongoing Phase 2 breast cancer trial wi...

Company receives FDA Approval to initiate multiple IDE studies, Including Path to Pivotal Trial in Breast Cancer Integrated LUM System with Drug, Device and Software Currently Under Investigation in Five Solid Tumor Cancers Wellesley, Mass., Sept. 6, 2017— Lumicell, Inc., a technology leader in the field of image-guided cancer surgery, today announced the initiation of clinical studies in breast cancer and prostate cancer with its LUM System. The initiation of the clinical trials is based...

Product innovation continues to advance under scientific leadership of company’s founder, W. David Lee Wellesley, Mass., Aug. 10, 2017— Lumicell, Inc., a technology leader in the field of image-guided cancer surgery, today announced the company’s progress with its product development of the Lumicell System, as well as the expansion of patent protection for the company’s product and technologies.  The foundation of Lumicell’s product development plan is the integration of thre...